News
IMNM
25.52
+0.51%
0.13
Immunome’s Strategic Acquisition to Revolutionize Cancer Treatment
TipRanks · 2d ago
Press Release: Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals, Inc. AL102 is a potential once-daily oral treatment for desmoid tumors. AL 102 is currently being evaluated in the randomized Phase 3 RINGSIDE international trial. Immunome is a biotechnology company focused on developing first-in-class targeted cancer therapies.
Dow Jones · 2d ago
*Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM
Dow Jones · 2d ago
Weekly Report: what happened at IMNM last week (0318-0322)?
Weekly Report · 3d ago
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
Worthington Steel, Inc. Shares jumped 18.8% to $37.92 on Friday. The company posted stronger-than-expected results for its third quarter. Dow Jones index fell around 50 points in Friday's session. Murano Global Investments PLC shares rose 147.5% after falling 46% on Thursday.
Benzinga · 6d ago
Weekly Report: what happened at IMNM last week (0311-0315)?
Weekly Report · 03/18 11:44
Weekly Report: what happened at IMNM last week (0304-0308)?
Weekly Report · 03/11 11:40
Weekly Report: what happened at IMNM last week (0226-0301)?
Weekly Report · 03/04 11:43
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
David Prince, professional trader at T3 Trading Group, discussed the biotech sector on Benzinga's "PreMarket Prep" Prince believes large biotech companies are looking to recapture growth through mergers and acquisitions. He sees lower interest rates as the next catalyst for the industry.
Benzinga · 02/28 17:51
Weekly Report: what happened at IMNM last week (0219-0223)?
Weekly Report · 02/26 11:59
IMUNON, Inc. Announces IMNN-101 Preclinical Data In SARS CoV-2 Published In Peer-Reviewed Journal Vaccine
Data Show Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccine Modality. The study was published in the peer-reviewed journal Vaccine. The company is developing a DNA vaccine for SARS-CoV-2.
Benzinga · 02/22 13:25
Leerink Partners Sticks to Their Buy Rating for Immunome (IMNM)
TipRanks · 02/22 05:18
Weekly Report: what happened at IMNM last week (0212-0216)?
Weekly Report · 02/19 12:02
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Immunome, Inc. Announced the closing of its underwritten public offering of 10,000,000 shares of its common stock. The gross proceeds to Immunome from the offering are $230.0 million. Immunome is a biotechnology company dedicated to developing first-in-class targeted cancer therapies.
Barchart · 02/16 15:05
Immunome Launches $200 Million Public Offering
TipRanks · 02/14 21:24
BUZZ-U.S. STOCKS ON THE MOVE-CME Group, Robinhood Markets, Citigroup
Dow Jones Industrial Average was up 0.21% on Wednesday. Nvidia topped Alphabet's market value to become the third-most valuable U.S. Company. Uber Technologies Inc. Was the top percentage gainer on the S&P 500. The Nasdaq Composite was up 1%.
Reuters · 02/14 16:22
BUZZ-Immunome slides on $200 mln equity offering
Immunome Inc's IMNM.O shares down 13.3% at $19.41 premarket. Cancer drug developer late Tues said sold 10 mln shares at $20, 10.7% discount to last sale. Firm announced $200 mln equity offering. IMNM shares surged 37% on Feb 6 after agreeing to buy a cancer drug.
Reuters · 02/14 14:05
GMBL, LICN and BDRX among pre-market losers
On the Move GMBL, LICN and BDRX among pre-market losers. QuidelOrtho Corporation (QDEL) -37% after Q4 earnings release. QDEL, GMBL and other companies are down in pre- market trading.
Seeking Alpha · 02/14 13:38
BUZZ-Immunome edges up after $200 mln equity offering
Immunome Inc's IMNM.O shares up 0.5% to $22.50 premarket after $200 mln equity offering. Cancer drug developer sold 10 mln shares at $20, 10.7% discount to last sale. Firm's stock has more than doubled YTD.
Reuters · 02/14 13:38
Immunome Prices Public Offering Of 10M Common Stock At $20/Share
The gross proceeds to Immunome from the offering are expected to be $200.0 million. The offering is expected to close on February 16, 2024. Immunome has granted the underwriters a 30-day option to purchase an additional 1,500,000 shares of its common stock.
Benzinga · 02/14 07:38
More
Webull provides a variety of real-time IMNM stock news. You can receive the latest news about Immunome Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMNM
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.